British journal of cancer

MGMT gene activity levels linked to outcomes in brain cancer treated with temozolomide and radiation

Circadian Biology Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Median overall survival for glioblastoma patients treated with temozolomide and radiotherapy was 12.4 months.

  • Methylation of the MGMT promoter was found to be an independent prognostic factor associated with prolonged progression-free survival and overall survival.
  • Cases with more than 35% methylation exhibited the longest survival, with a median progression-free survival of 19.2 months and overall survival of 26.2 months.
  • Significant differences in progression-free survival were observed between patients with intermediate or high methylation compared to unmethylated cases.
  • 86% of glioblastomas demonstrated homogeneous methylation status across multiple samples, indicating consistency in methylation patterns.
  • 58 out of 109 glioblastomas showed average methylation levels greater than non-neoplastic brain tissue in at least one clinical sample.

Simplified

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Related papers

Feb '12
MGMT gene changes and protein levels as predictors in brain tumor patients treated with carmustine wafers, radiation, and temozolomide after surgery
top 5% journal
cited by 72 papers
research support, non-u.s. gov't
Feb '13
Benefits of temozolomide combined with radiotherapy in standard treatment for new glioblastoma cases
cited by 22 papers
comparative study
Mar '11
MGMT mRNA levels predict outcomes in malignant glioma regardless of MGMT gene methylation
top 30% journal
cited by 100 papers
validation study
Mar '05
How MGMT gene silencing relates to temozolomide benefit in brain cancer
🏆 top 0.1% journal
cited by 6,201 papers
research support, non-u.s. gov't
Oct '15
IDH mutation and MGMT gene changes in glioblastoma: findings from a forward-looking patient registry
top 30% journal
cited by 133 papers
research support, non-u.s. gov't
Dec '14
Long-term temozolomide treatment is possible for new glioblastoma patients: experience with up to 101 treatment cycles
top 20% journal
cited by 67 papers
journal article
Mar '04
DNA repair gene methylation predicts treatment response in brain cancer patients receiving temozolomide
cited by 662 papers
clinical trial, phase ii
Mar '12
MGMT gene methylation linked to outcomes in glioblastoma patients treated with temozolomide and radiation
top 5% journal
cited by 45 papers
research support, non-u.s. gov't

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the circadian biology brief

issue #50
Afternoon workouts beat morning sessions for fat loss — and your genes may explain why
6 days ago7 studies
issue #49
Your body clock controls which drugs work — and a protein called gp78 is why
1 week ago7 studies
issue #48
A blood test can now estimate your internal clock time using just 60 proteins
2 weeks ago7 studies
issue #47
Your body clock controls liver fibrosis — and scientists just found the on/off switch
3 weeks ago7 studies
issue #46
Night shift workers' metabolomes fall out of sync — and glucose pays the price
4 weeks ago7 studies
issue #45
80% of FDA-approved drug targets show clock-dependent activity — timing may be everything
5 weeks ago7 studies
issue #44
Sleeping late on weekends is independently linked to higher cardiovascular disease risk
6 weeks ago7 studies
issue #43
A smartphone app cut mood episode recurrence 3.4x in people with depression and bipolar disorder
7 weeks ago7 studies
issue #42
Morning cancer immunotherapy linked to 49% vs 40% disease control rate in 969 patients
8 weeks ago7 studies
issue #41
Timing cancer treatment before 3pm nearly doubled survival in lung cancer patients
9 weeks ago7 studies
explore the archive
See more issues from the circadian biology brief